Toujeo Max Solostar is a drug owned by Sanofi Us Services Inc. It is protected by 20 US drug patents filed from 2018 to 2019. Out of these, 4 drug patents are active and 16 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 16, 2035. Details of Toujeo Max Solostar's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Toujeo Max Solostar's patents.

Latest Legal Activities on Toujeo Max Solostar's Patents

Given below is the list of recent legal activities going on the following patents of Toujeo Max Solostar.

Activity	Date	Patent Number
Today's Critical Events
Payment of Maintenance Fee, 8th Year, Large Entity	08 Nov, 2023	US9345750
Payment of Maintenance Fee, 4th Year, Large Entity	25 Jan, 2023	US10369291
Post Issue Communication - Certificate of Correction	13 Nov, 2019	US10369291
Payment of Maintenance Fee, 4th Year, Large Entity	08 Nov, 2019	US9345750
Recordation of Patent Grant Mailed Critical	06 Aug, 2019	US10369291
Patent Issue Date Used in PTA Calculation Critical	06 Aug, 2019	US10369291
Email Notification Critical	18 Jul, 2019	US10369291
Issue Notification Mailed Critical	17 Jul, 2019	US10369291
Dispatch to FDC	26 Jun, 2019	US10369291
Application Is Considered Ready for Issue Critical	20 Jun, 2019	US10369291

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Toujeo Max Solostar and ongoing litigations to help you estimate the early arrival of Toujeo Max Solostar generic.

Toujeo Max Solostar's Litigations

Toujeo Max Solostar been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 10, 2018, against patent number US8992486. The petitioner Mylan Pharmaceuticals Inc et al., challenged the validity of this patent, with Sanofi-Aventis Deutschland GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Toujeo Max Solostar's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US8679069	May, 2019	FWD Entered (11 Aug, 2020)	Sanofi-Aventis Deutschland	Pfizer Inc.
US8603044	September, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US8992486	September, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US8992486	October, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US9526844	September, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc
US9526844	September, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US9604008	September, 2018	FWD Entered (29 May, 2020)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US8679069	September, 2018	FWD Entered (02 Apr, 2020)	Sanofi-Aventis Deutshland GmbH	Mylan Pharmaceuticals Inc.
US9526844	May, 2019	Terminated-Other (20 Aug, 2019)	Sanofi-Aventis Deutschland	Pfizer Inc.
US9526844	May, 2019	Terminated-Other (19 Aug, 2019)	Sanofi-Aventis Deutschland	Pfizer Inc.
US8603044	May, 2019	Terminated-Other (15 Aug, 2019)	Sanofi-Aventis Deutschland	Pfizer Inc.
US8992486	May, 2019	Terminated-Other (15 Aug, 2019)	Sanofi-Aventis Deutschland	Pfizer Inc.
US9604008	May, 2019	Terminated-Other (15 Aug, 2019)	Sanofi-Aventis Deutschland	Pfizer Inc.
US9526844	September, 2018	Terminated-Denied (03 Apr, 2019)	Sanofi-Aventis Deutschland GmbH	Mylan Pharmaceuticals Inc.
US8992486	September, 2018	Terminated (19 Dec, 2018)	Sanofi-Aventis Deutschland GmbH et al.	Mylan Pharmaceuticals Inc et al.

FDA has granted some exclusivities to Toujeo Max Solostar. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Toujeo Max Solostar, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Toujeo Max Solostar.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

US patents provide insights into the exclusivity only within the United States, but Toujeo Max Solostar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Toujeo Max Solostar's family patents as well as insights into ongoing legal events on those patents.

Toujeo Max Solostar's Family Patents

Full family tree

Generic Launch

About Toujeo Max Solostar

Toujeo Max Solostar is a drug owned by Sanofi Us Services Inc. It is used for improving glycemic control in diabetes mellitus patients. Toujeo Max Solostar uses Insulin Glargine Recombinant as an active ingredient. Toujeo Max Solostar was launched by Sanofi Us Services in 2015.